title: Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment.
abstract: Irritable bowel syndrome (IBS) is the commonest cause of recurrent abdominal pain (RAP) in children in both more developed and developing parts of the world. It is defined by the Rome III criteria for functional gastrointestinal disorders. It is characterized by abdominal pain that is improved by defecation and whose onset is associated with a change in stool form and or frequency and is not explained by structural or biochemical abnormalities. It is estimated that 10%-15% of older children and adolescents suffer from IBS. IBS can be considered to be a brain-gut disorder possibly due to complex interaction between environmental and hereditary factors. The diagnosis of IBS is made based on the Rome III criteria together with ruling out organic causes of RAP in children such as inflammatory bowel disease and celiac disease. Once the diagnosis of IBS is made, it is important to explain to the parents (and children) that there is no serious underlying disease. This reassurance may be effective treatment in a large number of cases. Lifestyle modifications, stress management, dietary interventions and probiotics may be beneficial in some cases. Although there is limited evidence for efficacy of pharmacological therapies such as antispasmodics and antidiarrheals; these have a role in severe cases. Biopsychosocial therapies have shown encouraging results in initial trials but are beset by limited availability. Further research is necessary to understand the pathophysiology and provide specific focused therapies.
authors.affiliation: Bhupinder Kaur Sandhu, Siba Prosad Paul, Department of Pediatric Gastroenterology, Bristol Royal Hospital for Children, Bristol BS2 8BJ, United Kingdom.
authors.forename: Bhupinder Kaur
authors.initials: BK
authors.lastname: Sandhu
authors.affiliation: Bhupinder Kaur Sandhu, Siba Prosad Paul, Department of Pediatric Gastroenterology, Bristol Royal Hospital for Children, Bristol BS2 8BJ, United Kingdom.
authors.forename: Siba Prosad
authors.initials: SP
authors.lastname: Paul
mesh_terms: D015746:Abdominal Pain; D000293:Adolescent; D000930:Antidiarrheals / Q000627:therapeutic use; D002648:Child; D004358:Drug Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis* / Q000453:epidemiology* / Q000523:psychology / Q000628:therapy*; D008019:Life Style; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D010290:Parents; D019936:Probiotics / Q000627:therapeutic use; D011613:Psychotherapy; D012008:Recurrence; D012720:Severity of Illness Index; D013315:Stress, Psychological / Q000175:diagnosis; D016896:Treatment Outcome
chemical_list: D000930:Antidiarrheals; D010276:Parasympatholytics
keywords: Biopsychosocial therapies; Brain-gut disorder; Children; Irritable bowel syndrome; Lifestyle modifications; Recurrent abdominal pain; Rome III criteria